ASCO 2024: Hematologic Malignancies

CME

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2024 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 16, 2024

Expiration: February 15, 2025

Shaji K. Kumar
Shaji K. Kumar, MD
Jeffrey P. Sharman
Jeffrey P. Sharman, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1 2
Course Completed

References

  1. Facon T, Dimopoulous MA, Leleu XP, et al. Phase 3 study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7500.
  2. Facon T, Dimopoulous MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;[Epub ahead of print].
  3. Weisel K, Kumar S, Moreau P, et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Presented at: 4th European Myeloma Network Meeting; April 20-22, 2023. Abstract P09.
  4. Leleu XP, Hulin C, Lambert J, et al. Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7501.
  5. Leleu X, Hulin C, Lambert J, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;[Epub ahead of print].
  6. Sonneveld P, Dimopoulous MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2023;390:301-313.
  7. Rodriguez-Otero P, Moreau P, Dimopoulous MA, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7502.
  8. Trudel S, Beksac M, Pour L, et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract LBA105.
  9. Dimopouluos MA, Beksac M, Pour L, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;[Epub ahead of print].
  10. Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781-794.
  11. Hungria V, Robak P, Hus M, etc. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393-407.
  12. San Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  13. Costa LJ, Weisel KC, van de Donk NWCJ, et al. Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7504.
  14. Arnulf B, Kerre T, Agha ME, et al. Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7505.
  15. Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7508.
  16. van de Donk NWCJ, Garfall AL, Benboubker L, et al. Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7517.
  17. Hughes TP, Hochhaus A , Takahashi N, et al. ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): primary results. Presented at: 2024 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract LBA6500.
  18. Hochhaus A, Wang J, Kim DW, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;[Epub ahead of print].
  19. Imatinib [prescribing information]. East Hanover, NJ: Novartis; 2024.
  20. Jabbour EJ, Cortes JE, Kantarjian HM, et al. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13:1433-52.
  21. Chow EJ, Doody DR, Wilkes JJ, et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021;62:1203-1210.
  22. Yeung DT, Shanmuganathan N, Hughes TP, et al. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022;139:3474-3479.
  23. Asciminib [prescribing information]. East Hanover, NJ: Novartis; 2024.
  24. Cortes J, Quintás-Cardama A, Kantarjian HM, et al. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011;117:1113-22.
  25. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801-821.
  26. Kleppe M, Koche R, Zou L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;3:785-787.
  27. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.
  28. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
  29. Bewersdorf J, Ajufo H, Harrison C, et al. Spleen volume reduction predicts survival in myelofibrosis patients on pacritinib but not best available therapy: PERSIST-2 landmark overall survival analysis. Hemasphere. 2023;7(S3):e44640da.
  30. Mascarenhas J, Kremyanskaya M, Patriarca A, et al. MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naive myelofibrosis. J Clin Oncol. 2023;10;41:4993-5004.
  31. Rampal R, Grosicki S, Chraniuk, D, et al. Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naive patients with myelofibrosis. Presented at: 2024 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 6502.
  32. Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408-1414.
  33. Jabbour E, Tholouli E, Sandhu KS, et al. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study. Presented at: 2024 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract Abstract 6504.
  34. National Cancer Institute. Cancer stat facts: leukemia—acute myeloid leukemia (AML). seer.cancer.gov/statfacts/html/amyl.html. Accessed August 6, 2024.
  35. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;22;11:41.
  36. Singh A, Carraway HE. Overview of the management of higher-risk myelodysplastic syndromes. Cancer J. 2023;29:160-167.
  37. El-Jawahri A, Webb JA, Breffni H, et al. Integrating palliative care and hematologic malignancies: bridging the gaps for our patients and their caregivers. Am Soc Clin Oncol Educ Book. 2024;44:e432196.
  38. El-Jawahri A, Kavanaugh A , Greer JA, et al. Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy. Presented at: 2024 American Society of Clinical Oncology annual meeting; May 31 -June 4, 2024. Abstract LBA6508.
  39. Kim JA, Hahn U, Kim W-S, et al. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7033.
  40. Epcoritamab [prescribing information]. Plainsboro, NJ: Genmab; 2024.
  41. Glofitamab [prescribing information]. South San Francisco, CA: Genentech; 2023.
  42. Karimi Y, Thieblemont C, Ghesquieres H, et al. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7039.
  43. Bartlett NL, Dickinson M, Hutchings M, et al. Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): results from a phase I/II study. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7020.
  44. Habib A, Welkie R, Butman J, et al. Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract LBA7005.
  45. Silva Corraes ADM, Baranwal A, Bansal R, et al. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7038.
  46. Furqan F, Palen K, Johnson B, et al. Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma. Presented at: American Society of Clinical Oncology annual meeting; May 31 - June 4, 2024. Abstract 7043.